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Abstract  
Background: The aim of the present study is to assess the relationship between body mass 
index (BMI) and long-term clinical outcomes in retrograde endovascular recanalization (ER) 
regarding chronic total occlusions (CTOs) of the infra-inguinal lower limb arteries. 
Methods: The study included patients who underwent retrograde ER of CTOs localized in  
superficial, popliteal or below-the-knee arteries. During follow-up, major adverse cardiac and 
cerebrovascular (MACCE) and major adverse lower limb events were evaluated (MALE). 
MALE was defined as amputation, target lesion re-intervention, target vessel re-intervention 
and surgical treatment.  
Results: The study included 405 patients at the mean age of 67.2 ± 10.4. The authors divided 
the overall group of patients according to BMI into < 25 (n = 156, 38.5%) and ≥ 25 kg/m2 (n 
= 249, 61.5%), and then into < 30 (n = 302, 75.8%) and ≥ 30 kg/m2 (n = 103, 24.2%). During 
the average follow-up 1,144.9 ± 664.3 days, the mortality rate was higher in the group of 
patients with BMI < 25 kg/m2 (10.5% vs. 5.3%, p = 0.051), and in the group of patients with 
 
 
BMI < 30 kg/m2 (8.7% vs. 2.9%, p = 0.048). The comparison of Kaplan-Meier curves 
revealed borderline differences when assessing months to death for the BMI < 25 kg/m2 (p = 
0.057) and BMI < 30 kg/m2 (p = 0.056) grouping variables. 
Conclusions: Obese and overweight patients undergoing CTO ER of the lower limb arteries 
from retrograde access are related to lower death rates during long-term follow-up.  
Key words: lower limb atherosclerosis, chronic total occlusions, retrograde access, 
clinical outcomes, body mass index 
 
 
INTRODUCTION 
Intermittent claudication is becoming a more frequent symptom due to population 
aging and progress in the effective treatment of other diseases such as ischemic heart disease 
or respiratory disorders, which result in reduced exercise tolerance. This, consequently causes 
a more frequent clinical image of peripheral arterial disease (PAD) symptoms. Endovascular 
revascularization (ER) is the treatment of choice in a majority of patients with symptomatic 
PAD. In the case of patients diagnosed with chronic total occlusion (CTO) of the lower limb 
arteries and failure of ER with antegrade access, retrograde access is a treatment option that 
can be offered prior to referring a patient to a vascular surgeon or possible optimal medical 
therapy. Several publications estimating long-term results of regular ER of PAD patients have 
been published [1, 2]. The relationship between body mass index (BMI) and mortality rate in 
patients treated with percutaneous interventions has been widely investigated in patients with 
stable coronary artery disease (CAD), acute coronary syndromes and heart failure [3–6]. The 
relationship between BMI and mortality in patients with PAD, especially those undergoing 
ER, is scarcely investigated and there are only a few publications available in this area [7–9].  
Therefore, the aim of the present study is to evaluate the relationship between BMI 
and the long-term results of endovascular treatment from retrograde access in patients with 
PAD. 
 
METHODS 
Study population  
This study was planned as a prospective observational study of consecutive patients 
who underwent retrograde recanalization of CTO localized in the superficial femoral artery 
(SFA), popliteal artery (PA) or below-the-knee arteries. At two experienced and cooperating 
centers, all consecutive patients were enrolled after at least one unsuccessful antegrade 
 
 
recanalization of CTO who qualified for the retrograde approach. Each patient was also 
qualified for endovascular treatment after consultation by a vascular surgeon. The main 
factors disqualifying patients from surgical revascularization were anatomical reasons (lack of 
vessel circumference in the course of atherosclerosis), morphological (narrow and winding 
peripheral vessels) or poor clinical condition and high perioperative risk. Antegrade failure 
was defined as the inability to wire the distal part of the vessel after the occlusion via the 
access site, located in the contralateral artery or proximal to the CTO lesion. The inability to 
wire the distal part of the CTO was both due to a failure to penetrate the lesion or because of a 
failure to return to the arterial lumen after subintimal recanalization in selected cases with 
suitable anatomy and morphology of target lesions. According to the local protocol, patients 
were screened for concomitant diseases, risk factors, and medication prior to the procedure. In 
all patients before the procedure, the ankle–brachial index was examined and severity of PAD 
was assessed according to Rutherford and/or Fontaine scale. The decision regarding 
retrograde recanalization and access site was based on prior angiography. The procedure of 
retrograde recanalization was performed under local anesthesia and required two access sites: 
antegrade and retrograde. Both, proximal and distal punctures were done under the guidance 
of vascular ultrasound and/or fluoroscopy. The choice of the type of antegrade access site was 
determined by many factors, including anatomical conditioning, type of vascular lesions 
(dissemination, calcifications, length), technical possibilities (having sufficiently long 
catheters), type of occlusions, its length and probability of blood flow restoration. For the 
proximal access site, the contralateral femoral artery was usually used, and 6 Fr vascular 
sheaths belonged to the most used. The distal access site was usually chosen in the 
reconnection area of the artery (needle: 12–15 mm, 21G). In case of instability of distal 
puncture, 4 Fr vascular sheaths were needed to obtain support during the procedure. In a few 
cases, the distal access site was also used for the revascularization of more peripheral parts of 
the artery. The hydrophilic 0.035’’ guidewire was used for the antegrade access site. 
Occlusions were crossed from the retrograde access site with a non-hydrophilic 0.018’’ 
guidewire. After crossing the occlusion with a wire via the retrograde approach, pre-dilatation 
with a balloon catheter was performed. Stent implantation was based on the decision of the 
operator. After the procedure, the distal sheet was removed immediately, and the proximal 
one was maintained for up to 4 h when the femoral artery was punctured, which was 
conditioned by unfractionated heparin use. Due to dissection, in some cases, the balloon 
inflations were performed from both ante- and retrograde access (kissing balloon technique) 
to tear the dissection and facilitate capturing the wire with the diagnostic catheter. The first 
 
 
antegrade puncture site was used to visualize the vessel during the retrograde access 
procedure and was defined as the angiography first access site. In some patients, due to 
anatomical, morphological or technical problems, it was not possible to reach the distal part of 
the artery treated with retrograde access for angiography, and these patients had to undergo 
puncture of another artery which was defined as the second, third or fourth antegrade 
angiography access site. In periprocedural treatment, all patients received double antiplatelet 
therapy: acetylsalicylic acid 75 mg — permanently, and clopidogrel 75 mg for 3 months, a 
high dose of statin and according to a local protocol, low-molecular-weight heparin for 4 
weeks. In the long-term follow-up, which lasted on average 1,144.9 ± 664.3 days, patients 
were evaluated for major adverse cardiac and cerebrovascular events (MACCE) as well as 
major adverse limb events (MALE). Data were collected between 2006 and 2016. In this 
paper, MACCE were predefined as death, stroke/transient ischemic attack, myocardial 
infarction, percutaneous coronary intervention (PCI) or coronary artery bypass grafting 
(CABG). MALE was defined as amputation, target lesion re-intervention, target vessel re-
intervention and surgical treatment. Due to shortages in the available database, the level of 
amputation was not highlighted in the presented publication and alike high-, mid- and low-
amputations, they were included in the term of overall amputation rate. The protocol 
complied with the Declaration of Helsinki, and all participants provided written informed 
consent before enrollment. 
 
Statistical analysis 
Categorical variables are presented as numbers and percentages. Continuous variables 
are expressed as mean ± standard deviation or median and interquartile range. Normality was 
assessed using the Shapiro-Wilk test. Equality of variance was assessed using Levene’s test. 
Differences between groups were compared using the Student’s or Welch’s t-test depending 
on the equality of variances for normally distributed variables. The Mann-Whitney U test was 
applied in  cases of continuous variables without normal distribution. Categorical variables 
were compared via the Pearson chi-squared or the Fisher exact test if 20% of cells had a count 
less than 5. Ordinal variables were compared with the Cochran-Armitage trend test. To 
analyze survival rate in selected risk groups, Kaplan-Meier curves were drawn. The log-rank 
statistic was used to test the differences in the outcome between groups. All statistical 
analyses were performed with JMP®, Version 13.1.0 (SAS Institute INC., Cary, NC, USA). 
 
RESULTS 
 
 
General characteristics 
In total, 405 patients were included in the study. There were 156 (38.5%) patients with 
BMI < 25 kg/m2 and 302 (74.6%) patients with BMI < 30 kg/m2. In both groups, patients with 
lower BMI were older when stratified for BMI < 25 kg/m2 (68.3 ± 11.1 vs. 66.51 ± 9.8, p = 
0.09) and also for BMI < 30 kg/m2 (68.2 ± 10.7 vs. 64.4 ± 8.9, p = 0.006), compared to 
patients with a higher BMI. Patients with higher BMI suffered from diabetes more often when 
stratified for BMI ≥ 25 kg/m2 (35.9% vs. 59%, p < 0.0001) and for BMI ≥ 30 kg/m2 (43% vs. 
70.9%, p < 0.0001), as well as from CAD when classified for BMI ≥ 25 kg/m2 (35.3% vs. 
45.4%, p = 0.04), and for BMI ≥ 30 kg/m2 (38.7% vs. 49.5%, p = 0.055). A general 
characterization of all groups assessed in the current study is presented in Table 1.  
 
Clinical presentation  
When stratified for BMI < 25 kg/m2, the clinical stage of ischemic changes before 
angioplasty was more advanced in patients with lower BMI, both when using the Rutherford 
(p = 0.04) and Fontaine classifications (p = 0.01), however, when stratified for BMI < 30 
kg/m2, there were no significant differences in clinical presentation of ischemia before 
angioplasty between patients with lower and higher BMI (p = 0.6 and p = 0.96). This is 
presented in Table 2.  
 
Angiography and procedural indices 
According to the Trans-Atlantic Inter Society Consensus (TASC II) classification, the 
authors did not observe any significant differences between patients with lower and higher 
mean BMI values when stratified for BMI < 25 and < 30 kg/m2. In general, lesions tended to 
occur longer in patients with lower BMI in both stratifications, and reached statistical 
significance for the common femoral artery when stratified for BMI < 25 kg/m2 (13.4 ± 21.8 
mm vs. 8 ± 13.8 mm, p = 0.04) and the popliteal artery when stratified for BMI < 30 kg/m2 
(51.2 ± 52.5 mm vs. 34.3 ± 42.9 mm, p = 0.02). Angiographic indices are presented in Table 
2.  
 
Clinical endpoints 
During the 120-month-long follow-up period, the authors did not observe significant 
differences in reintervention or amputation rates, the frequency of lower extremity bypass 
surgery and/or stroke as well as transient ischemic attack rates between patients with higher 
and lower BMI when stratified for < 25 kg/m2 and < 30 kg/m2. Nonetheless, death rate at the 
 
 
end of the follow-up period was higher in patients with lower BMI when stratified for BMI < 
25 kg/m2 (10.5% vs. 5.3%, p = 0.051) and for BMI < 30 kg/m2 (8.7% vs. 2.9%, p = 0.048). 
This is presented in Table 3. However, the long-rank test considered months to death for 
grouping variable BMI < 25 kg/m2 revealed higher death rates in the group of patients with 
lower BMI, but without statistical significance (p = 0.057). Also, analysis for grouping 
variable BMI < 30 kg/m2 demonstrated a significant tendency without statistical significance 
(p = 0.056). This is presented in Figure 1A and B as well as Table 4. The long-rank test 
reflecting months to death for grouping variable BMI did not reveal significant differences (p 
= 0.26) after division into six subgroups (underweight: BMI < 18 kg/m2, normal-weight: 18 
kg/m2 ≤ BMI < 25 kg/m2; overweight: 25 kg/m2 ≤ BMI < 30 kg/m2; class 1 obesity: 30 kg/m2 
≤ BMI < 35 kg/m2; class 2 obesity: 35 kg/m2 ≤ BMI < 40 kg/m2; class 3 obesity: BMI ≥ 40 
kg/m2). Nevertheless, during the first 12 months of follow-up, mortality rate was highest in 
the subgroup of underweight and class 3 obesity patients. This is presented in Figure 2 and 
Table 5.  
 
Clinical endpoints and COPD 
In the current study, 43 patients diagnosed with chronic obstructive pulmonary disease 
(COPD; 10.6%), were divided according to BMI, similarly as in the overall group of patients. 
The authors compared clinical outcomes between patients with BMI < 25 kg/m2 (51.2%) and 
≥ 25 kg/m2 (48.8%) and between patients with BMI < 30 kg/m2 (81.4%) and ≥ 30 kg/m2 
(18.6%). Particular clinical endpoints were higher in patients with lower BMI; however, they 
did not reach statistical significance when stratified for BMI < 25 kg/m2 (reinterventions: 
19.05% vs. 9.52%, p = 0.66; deaths: 14.29% vs. 4.76%, p = 0.6 and lower extremity bypass 
surgery: 21.05% vs. 5%, p = 0.18) and for BMI < 30 kg/m2 (reinterventions: 17.65% vs. 0%, 
p = 0.57; deaths: 11.76% vs. 0%, p = 0.57; amputations: 14.29% vs. 12.5%, p = 1.0; lower 
extremity bypass surgery: 15.63% vs. 0%, p = 0.56).  
 
DISCUSSION 
The main finding of the current study is that underweight, normal-weight and 
overweight patients are at increased risk of death prior to endovascular treatment of CTOs of 
the lower limb infra-inguinal arteries during the long-term follow-up period in comparison to 
the group of obese patients.  
 
 
Several studies assessing the impact of BMI calculated before PCI have been 
published to date [3–5]. It was demonstrated that in the case of underweight, normal-weight 
and extremely obese patients with a BMI ≥ 35 kg/m2 present an increased death rate 
compared to other weights during the long-term follow-up period [3]. This correlation in 
patients with CAD treated using PCI has been described as the “obesity paradox”. Several 
explanations and mechanisms have been attributed to this phenomenon. One of them is that 
obese patients are younger, which correlates to longer survival rate [3]. This relationship was 
also visible in the current analysis concerning patients with PAD. However, previously 
published studies combined the lower mean age with smaller rates of co-morbidities and less 
advanced atherosclerosis [3]. While some patterns of more advanced atherosclerosis like 
lesion length or the percentage of CTO lesions in patients with lower BMI were observed in 
the current study, the rate of co-morbidities such as diabetes and coronary artery disease 
(CAD) was significantly higher in patients from higher BMI groups (≥ 25 kg/m2 and ≥ 30 
kg/m2). Previously published studies included endocrine status modified by adipose tissue and 
the size of coronary vessels among the other factors possibly responsible for the protective 
effect of obesity in patients with CAD treated using PCI [10, 11]. Obesity is widely 
recognized as a risk factor of atherosclerosis and related complications such as cardiovascular 
events and mortality. However, there are some data that do not confirm this relationship in 
patients with CAD [12]. Despite the fact that the World Health Organization endorses the use 
of BMI as the best measure for screening obesity, some studies demonstrated that it is not 
sufficient in assessing the amount of adipose tissue but is related to other indices such as 
waist/hip ratio [13, 14]. Bioelectrical impedance analysis and muscle handgrip strength 
measurement are among the best devices for estimating muscle mass and adipose tissue [15]. 
Another factor that may affect mortality in obese patients is better adherence to medical 
recommendations in the field of pharmacotherapy and prevention in this group of patients 
[16]. Antiplatelet and antithrombotic therapy related to bleeding complications was also found 
to have a potential relationship with clinical outcomes after PCI and CAD [17, 18].  
The research related to the relationship between long-term survival and BMI in 
patients with PAD is very limited [7–9]. To our knowledge, this is the first study describing 
the relationship between BMI and clinical outcomes in patients with PAD treated using 
angioplasty from retrograde access. The study published by Kumakura et al. [7] including 652 
patients with PAD confirmed the presence of the “obesity paradox” phenomenon in this group 
of patients. The authors indicated glomerular filtration rate, critical limb ischemia (CLI) and 
diabetes to be among other predictors of mortality in patients with PAD. The study published 
 
 
by Murata et al. [8] including 1,088 patients and comprising 1,306 limbs with critical 
ischemia treated with endovascular therapy confirmed the previously discovered relationship 
in patients with CAD treated using PCI. This study demonstrated that underweight patients 
with CLI are at increased risk of death during the median follow-up of 1.5 years compared to 
overweight and obese patients. Also, normal weight was associated with poorer survival rate 
during the follow-up compared to overweight and obese patients [8]. Furthermore, age, heart 
failure, aortic valve stenosis, renal failure, serum albumin, medication with anticoagulants and 
non-ambulatory status were found to be negative predictors related to all-cause mortality [8]. 
Among the possible mechanisms, the authors suggest that malnutrition, related to low 
triglyceride level in patients with PAD, may be related to increased risk of death [7]. One of 
the published studies attributed the “obesity paradox” phenomenon in patients with PAD to 
the presence of concomitant COPD [19]. A similar correlation in patients with COPD 
between BMI and mortality has been previously demonstrated [20]. The incidence of COPD 
in the study published by Galal et al. [19] almost reached 47%, while in our study, it was only 
slightly above 10%. The impact of COPD in the current study was too low to modify the 
general relationship between BMI and mortality. Moreover, among the subgroup of patients 
with COPD in the current study, the relationship between death rate and BMI was not 
significant during the follow-up period. Considering the discussions on the issue of a number 
of potential mechanisms contributing to the development of the so-called “obesity paradox” in 
patients with CAD and PAD treated with percutaneous interventions, the role of sarcopenia 
has been superficially discussed. It has been demonstrated in several studies that sarcopenia is 
associated with increased mortality [21, 22]. The so-called U-shaped mortality curve relation 
to BMI could be owed to sarcopenia in underweight patients, while increased death rates in 
patients from severe and higher obesity classes may be related to the overwhelming influence 
of negative factors connected with obesity such as inflammatory processes or oxidative stress 
and lipid disorders [3].  
In the case of patients with reduced body mass, muscle mass plays crucial role, and it 
has been demonstrated in the group of patients with COPD undergoing rehabilitation that both 
resistance training as well as endurance training have a positive effect on mortality [23]. For 
patients with PAD endurance training may be difficult to achieve due to limited walking, but 
any physical activity leading to increased muscle mass seems to be beneficial and should be 
recommended for every patient with PAD. In addition, every patient undergoing ER with 
PAD should be informed about the fact that underweight and lower body weight is associated 
with increased mortality in the follow-up period. It should be remembered that the risk of 
 
 
revascularization, even in patients with a significantly higher risk of death in the follow-up 
period due to low body weight at baseline, is lower in patients treated percutaneously than in 
surgery. Therefore, in the case of limb threat with amputation and the possibility of 
percutaneous treatment, it does not seem advisable to postpone the procedure in order to 
increase muscle mass and body weight in terms of improving prognosis. 
 
Limitations of the study 
Several limitations can be attributed to the current study. One of them is that the 
current group of patients was extracted from a group of 834 patients treated from retrograde 
access and was limited to 405 patients due to lack of BMI data, despite the fact that the BMI 
deficiencies were random and were not associated with any particular factor. This could have 
significantly affected the results.  
 
CONCLUSIONS  
The BMI value at baseline in patients with PAD undergoing ER of CTOs of the infra-
inguinal lower limb arteries from retrograde access is associated with mortality during the 
follow-up period. Underweight and normal-weight persons are at increased risk of death after 
angioplasty when compared to obese individuals. Therefore, any physical activity leading to 
increased muscle mass seems to be beneficial and should be recommended to every PAD 
patient.  
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Table 1. General characteristics and clinical presentation. 
 < 25 kg/m2 ≥ 25 kg/m2 P < 30 kg/m2 ≥ 30 kg/m2 P 
General characteristics 
Age [years] 68.3 ± 11.1 66.5 ± 9.8 0.09W 68.2 ± 10.7 64.4±8.9 0.006U 
Gender, males 91 (58.3%) 162 (65.1%) 0.17P 192 (63.6%) 61 (59.2%) 0.43P 
COPD 22 (14.1%) 21 (8.4%) 0.07P 35 (11.6%) 8 (7.8%) 0.27P 
Hypertension 141 (90.4%) 232 (93.2%) 0.31P 274 (90.7%) 99 (96.1%) 0.08P 
Diabetes 56 (35.9%) 147 (59%) < 0.0001P 130 (43%) 73 (70.9%) < 0.0001P 
Renal failure 23 (14.7%) 44 (17.7%) 0.44P 46 (15.2%) 21 (20.4%) 0.22P 
Coronary artery disease 55 (35.3%) 113 (45.4%) 0.04P 117 (38.7%) 51 (49.5%) 0.055P 
Hyperlipidemia 15 (88.2%) 27 (90%) 1.0F 30 (88.2%) 12 (92.3%) 1.0F 
Stroke/TIA  13 (8.3%) 12 (4.8%) 0.15P 22 (7.3%) 3 (2.9%) 0.11P 
Smoking 57 (55.3%) 68 (50%) 0.41P 92 (50.5%) 33 (57.9%) 0.33P 
Prior PTA 36 (23.1%) 59 (23.7%) 0.88P 67 (22.2%) 28 (27.2%) 0.3P 
Prior bypass 36 (23.1%) 59 (23.7%) 0.63P 33 (10.9%) 10 (9.7%) 0.72P 
Clinical presentation before angioplasty    
Rutherford classification:  
0 
1 
2 
3 
4 
5 
6 
 
0 (0%) 
13 (8.3%) 
16 (10.3%) 
18 (11.5%) 
36 (23.1%) 
28 (17.9%) 
45 (28.8%) 
 
0 (0%) 
18 (7.2%) 
43 (17.3%) 
47 (18.9%) 
52 (20.9%) 
29 (11.6%) 
60 (24.1%) 
0.04CA  
0 (0%) 
26 (8.6%) 
46 (15.2%) 
43 (14.2%) 
66 (21.8%) 
43 (14.2%) 
78 (25.8%) 
 
0 (0%) 
5 (4.8%) 
13 (12.6%) 
22 (21.4%) 
22 (21.4%) 
14 (13.6%) 
27 (26.2%) 
0.6CA 
Fontaine scale: 
2a 
2b 
3 
4 
 
16 (10.3%) 
33 (21.1%) 
34 (21.8%) 
73 (46.8%) 
 
21 (8.4%) 
95 (38.1%) 
47 (18.9%) 
86 (34.5%) 
0.01CA  
32 (10.6%) 
90 (29.8%) 
60 (19.9%) 
120 (39.7%) 
 
5 (4.8%) 
38 (36.9%) 
21 (20.4%) 
39 (37.9%) 
0.96CA 
CA — Cochran–Armitage test for trend; F — Fisher's exact test; P — Pearson's chi-squared test; S — Student's t-test; U — Mann-Whitney U test; PTA — percutaneous 
transluminal angioplasty; TIA — transient ischemic attack  
 
 
 
 
Table 2. Procedural indices: angiography, culprit artery and lesion. 
 < 25 kg/m2 ≥ 25 kg/m2 P < 30 kg/m2 ≥ 30 kg/m2 P 
TASC II:  
A 
B 
C 
D 
 
23 (16.8%) 
23 (16.8%) 
36 (26.3%) 
55 (40.1%) 
 
41 (19%) 
56 (25.9%) 
34 (15.7%) 
39 (37.9%) 
0.25CA  
53 (20.1%) 
52 (19.7%) 
55 (20.8%) 
104 (39.4%) 
 
11 (12.4%) 
27 (30.3%) 
15 (16.8%) 
36 (40.4%) 
0.76CA 
Treated leg:  
Left 
Left, right 
Right  
 
73 (46.8%) 
4 (2.6%) 
79 (50.6%) 
 
126 (50.6%) 
10 (4%) 
113 (45.4%) 
0.48P  
149 (49.3%) 
8 (2.6%) 
145 (48%) 
 
50 (48.5%) 
6 (5.8%) 
47 (45.6%) 
0.3P 
Angiography first access site:  
Brachial  
Femoral 
Radial  
 
15 (10.6%) 
73 (51.4%) 
54 (38%) 
 
15 (6.8%) 
128 (57.7%) 
79 (35.6%) 
0.32P  
24 (8.9%) 
142 (52.4%) 
105 (38.7%) 
 
6 (6.4%) 
59 (63.4%) 
28 (30.1%) 
0.18P 
Angiography number of access sites: 
1 
2 
3 
4 
 
116 (81.7%) 
23 (16.2%) 
3 (2.1%) 
0 (0%) 
 
178 (79.5%) 
42 (18.7%) 
2 (0.9%) 
2 (0.9%) 
0.58CA  
214 (78.7%) 
52 (19.1%) 
5 (1.8%) 
1 (0.4%) 
 
80 (85.1%) 
13 (13.8%) 
0 (0%) 
1 (1.1%) 
0.23CA 
Angiography first access side: 
Right 
Left  
 
100 (70.4%) 
42 (29.6%) 
 
155 (69.2%) 
69 (30.8%) 
0.8P  
191 (70.2%) 
81 (29.8%) 
 
64 (68.1%) 
30 (31.9%) 
0.15P 
Iliac artery — significant lesion 35 (24.6%) 42 (18.9%) 0.19P 58 (21.2%) 19 (20.9%) 0.94P 
Deep femoral artery – significant lesion 12 (8.4%) 9 (4.1%) 0.08P 19 (7%) 2 (2.2%) 0.09P 
Common femoral artery  
Tortuosity: slight 
 
9 (7.9%) 
 
9 (5.5%) 
 
0.43P 
 
14 (6.7%) 
 
4 (5.9%) 
 
1.0F 
 
 
Chronic total occlusion  
Calcification:  
slight 
severe 
Lesion length [mm] 
10 (8.7%) 
 
23 (20.2%) 
11 (9.6%) 
13.4 ± 21.8 
4 (2.4%) 
 
34 (20.9%) 
6 (3.7%) 
8 ± 13.8 
0.02P 
 
0.11CA 
 
0.04U 
11 (5.2%) 
 
46 (22%) 
14 (6.70%) 
10.7 ± 18.5 
3 (4.4%) 
 
11 (16.2%) 
3 (4.4%) 
8.6 ± 15.1 
1.0F 
 
0.2CA 
 
0.42U 
Superficial femoral artery: 
Tortuosity:  
slight 
severe  
Chronic total occlusion  
Calcification:  
extreme 
severe 
slight 
Lesion length, mm 
 
 
52 (38%) 
3 (2.2%) 
63 (45%) 
 
1 (0.73%) 
30 (21.9%) 
59 (43.1%) 
107 ± 97 
 
 
67 (31.9%) 
6 (2.9%) 
103 (47.7%) 
 
1 (0.5%) 
53 (25.2%) 
86 (40.9%) 
74.8 ± 36.3 
 
 
0.42CA 
 
0.61P 
 
0.65CA 
 
 
0.97U 
 
 
91 (34.9%) 
7 (2.7%) 
122 (45.9%) 
 
2 (0.8%) 
64 (24.5%) 
109 (41.8%) 
106.9 ± 98.6 
 
 
28 (32.6%) 
2 (2.3%) 
44 (48.9%) 
 
0 (0%) 
19 (22.1%) 
36 (41.9%) 
108.2 ± 95.9 
 
 
0.65CA 
 
0.61P 
 
0.46CA 
 
 
0.92U 
Popliteal artery — lesion length  52.4 ± 54.9 43.6 ± 47.7 0.24U 51.2 ± 52.5 34.3 ± 42.9 0.02U 
Tibio-fibular trunk — significant lesion 41 (28.9%) 52 (23.4%) 0.24P 74 (27.1%) 19 (20.9%) 0.23P 
Tibialis anterior artery — significant lesion 70 (49.3%) 105 (47.3%) 0.7P 133 (48.7%) 42 (46.1%) 0.67P 
Peroneal artery — significant lesion  64 (45.1%) 79 (35.6%) 0.07P 112 (41%) 31 (34.1%) 0.23P 
Tibialis posterior artery — significant lesion 86 (60.6%) 106 (47.7%) 0.01P 133 (48.7%) 42 (46.1%) 0.67P 
Contrast volume [mL] 106.5 ± 67.8 119.4 ± 77.4 0.12U 110.9 ± 70.7 124.5 ± 82.4 0.19U 
Hospitalization time [days] 5.44 ± 4.6 5 ± 4.7 0.11U 5.4 ± 4.8 4.7 ± 4.3 0.2U 
Intraprocedural complications  4 (2.8%) 11 (4.9%) 0.32P 12 (4.4%) 3 (3.2%) 0.76F 
Major vascular complications 5 (3.52%) 5 (2.2%) 0.51F 9 (3.3%) 1 (1.1%) 0.46F 
Minor vascular complications  17 (12%) 26 (11.6%) 0.9P 33 (12.1%) 10 (10.6%) 0.7P 
CA — Cochran–Armitage test for trend; F — Fisher's exact test; P — Pearson's chi-squared test; TASC — Trans-Atlantic Inter Society Consensus; U — Mann-Whitney U 
test 
 
 
Table 3. Study endpoints 
 
 
 < 25 kg/m2 ≥ 25 kg/m2 P < 30 kg/m2 ≥ 30 kg/m2 P 
Re-PTA 47 (30.72%) 72 (29.15%) 0.73P 89 (29.97%) 30 (29.13%) 0.87P 
Days to Re-PTA 130.6 ± 125.4 196.9 ± 339.6 0.47U 151.3 ± 202.2 228.2 ± 427.7 0.07U 
Stroke/TIA 2 (1.3%) 5 (2%) 0.71F 5 (1.68%) 2 (1.94%) 1F 
Days to stroke/TIA 66.5 ± 47.4 130.6 ± 113.9 0.69U 150.8 ± 92.1 16 ± 12.7 0.052U 
Death 16 (10.5%) 13 (5.3%) 0.051P 26 (8.7%) 3 (2.9%) 0.048F 
Days to death 249.4 ± 360.7 537.8 ± 896.9 0.86U 310.5 ± 472.5 969.7 ± 1650.9 0.69U 
Amputation 24 (15.7%) 30 (12.4%) 0.35P 38 (12.8%) 16 (16.2%) 0.4P 
Days to amputation 87.6 ± 103.7 60.9 ± 87.4 0.36U 76.1 ± 102.1 64.9 ± 78 0.84U 
Lower extremity bypass 6 (4.3%) 9 (4.1%) 0.93P 10 (3.7%) 5 (5.6%) 0.54F 
Days to lower extremity bypass 48.5 ± 69.1 95.3 ± 90.8 0.19U 128.8 ± 91.2 76.6 ± 83.6 0.15U 
F — Fisher's exact test; P — Pearson's chi-squared test; PTA — percutaneous transluminal angioplasty; S — Student's t-test; TIA — transient ischemic attacks; U — Mann-
Whitney U test 
 
Table 4. Cumulative risk of study endpoints according to body mass index (BMI) status. 
BMI   0 M 12 M 24 M 36 M 48 M 60 M 72 M 84 M 96 M 108 M 120 M 
< 25 At risk 153 92 35 10 5 3 3 3 3 3 2 
CNE 0 13 14 15 16 16 16 16 16 16 16 
≥ 25 At risk 247 170 85 23 9 2 2 2 1 1 – 
CNE 0 10 10 10 11 12 12 12 13 13 – 
< 30 At risk 297 188 88 25 10 4 4 4 4 4 2 
CNE 0 21 22 23 25 26 26 26 26 26 26 
≥ 30 At risk 103 74 32 8 4 1 1 1 – – – 
CNE 0 2 2 2 2 3 3 3 – – – 
Total At risk 400 262 120 33 14 5 5 5 4 4 2 
CNE 0 23 24 25 27 28 28 28 29 29 29 
CNE — cumulative number of events, M — months 
 
 
 
 
Table 5. Cumulative risk of death according to body mass index (BMI) in selected intervals. 
BMI   0 M 12 M 24 M 36 M 48 M 60 M 72 M 84 M 96 M 108 M 120 M 
< 18.5 At risk 8 2 1 – – – – – – – – 
CNE 0 1 1 – – – – – – – – 
18.5 ≤ BMI < 25 At risk 145 90 34 10 5 3 3 3 3 3 2 
CNE 0 12 13 14 15 15 15 15 15 15 15 
25 ≤  BMI < 30 At risk 144 96 53 15 5 1 1 1 1 1 – 
CNE 0 8 8 8 9 10 10 10 10 10 – 
30 ≤ BMI < 35 At risk 77 57 25 8 4 1 1 1 – – – 
CNE 0 1 1 1 1 2 2 2 – – – 
35 ≤ BMI < 40 At risk 15 12 6 – – – – – – – – 
CNE 0 0 0 – – – – – – – – 
BMI ≥ 40 At risk 11 5 1 – – – – – – – – 
CNE 0 1 1 – – – – – – – – 
CNE — cumulative number of events; M — months
 
 
Figure 1. A. Months to death for grouping variable body mass index (BMI) < 25 kg/m2. The 
log-rank test p-value is equal to 0.057; B. Months to death for grouping variable BMI < 30 
kg/m2. The log-rank test p-value is equal to 0.056. 
 
 
 
Figure 2. Months to death for grouping variable body mass index. The log-rank test p-value 
is equal to 0.26.  
 


